Advertisement
UK markets close in 4 hours 7 minutes

  • FTSE 100

    8,069.13
    +45.26 (+0.56%)
     

  • FTSE 250

    19,736.67
    +137.28 (+0.70%)
     

  • AIM

    753.99
    +4.81 (+0.64%)
     

  • GBP/EUR

    1.1603
    +0.0015 (+0.13%)
     

  • GBP/USD

    1.2377
    +0.0027 (+0.22%)
     

  • Bitcoin GBP

    53,462.27
    +74.50 (+0.14%)
     

  • CMC Crypto 200

    1,420.80
    +6.04 (+0.43%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    81.50
    -0.40 (-0.49%)
     

  • GOLD FUTURES

    2,313.60
    -32.80 (-1.40%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    18,070.53
    +209.73 (+1.17%)
     

  • CAC 40

    8,102.95
    +62.59 (+0.78%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

Reuters

(Reuters) - AstraZeneca's (AZN.L) first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

The drug is currently approved as an add-on treatment for severe eosinophilic asthma in the United States, the European Union, Japan and several other countries.

Fasenra failed to meet its target in the final-stage trial, named Galathea, this month.

(Reporting By Justin George Varghese in Bengaluru; Editing by David Goodman)